MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
84.57
-0.59 (-0.70%)
As of 12:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close85.16
Open84.91
Bid84.61 x 1100
Ask84.62 x 800
Day's Range84.40 - 85.22
52 Week Range66.10 - 87.35
Volume3,043,340
Avg. Volume9,792,042
Market Cap216.519B
Beta (3Y Monthly)0.32
PE Ratio (TTM)23.71
EPS (TTM)3.57
Earnings DateOct 29, 2019
Forward Dividend & Yield2.20 (2.58%)
Ex-Dividend Date2019-09-13
1y Target Est96.33
Trade prices are not sourced from all markets
  • These 3 Long-Term Dividend Payers Offer a High Forward Yield
    GuruFocus.com

    These 3 Long-Term Dividend Payers Offer a High Forward Yield

    Taiwan Semiconductor Manufacturing Co. Ltd. tops the list Continue reading...

  • Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
    Zacks

    Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids

    Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.

  • Merck's Two HIV Drugs Get FDA Approval for Expanded Use
    Zacks

    Merck's Two HIV Drugs Get FDA Approval for Expanded Use

    Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.

  • Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label
    Zacks

    Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label

    CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.

  • Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC
    Zacks

    Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC

    Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.

  • Company News for Sep 23, 2019
    Zacks

    Company News for Sep 23, 2019

    Companies In The News Are: MDR, MRK, NFLX, XLNX

  • PR Newswire

    New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care

    Not intended for UK-based media Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, ...

  • PR Newswire

    New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

    Not intended for distribution in the USA , Canada or the UK Key ESMO Abstracts # BAVENCIO ® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX ® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase ...

  • Benzinga

    The Week Ahead In Biotech: Spotlight On ESMO Conference

    Biotech stocks put up a muted performance in the week ended Sept. 20 amid conference presentations and FDA approvals. Johnson & Johnson (NYSE: JNJ )'s Janssen unit received an FDA nod for label expansion ...

  • Reuters

    US STOCKS-Wall St gains on stimulus cues, U.S.-China trade progress

    U.S. stocks ticked higher on Friday, as cues of easing monetary policy around the globe and signs of further co-operation on Sino-U.S. trade talks kept the S&P 500 within 1% of a record high. China cut its new one-year benchmark lending rate for the second month in a row, days after the Federal Reserve and the European Central Bank reduced borrowing costs and left the door open for further monetary stimulus. The S&P 500 and Nasdaq were set to end the week little changed after a rough start, sparked by attacks on Saudi oil facilities.

  • GlobeNewswire

    BriaCell Announces Private Placement of up to $600,000

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company for gross proceeds of up to approximately C$600,000 at a price per common share of C$0.07. The closing of the Offering is scheduled to occur on or about September 26, 2019.  All securities issued under the Private Placement will be subject to a hold period expiring 4 months plus 1 day following the closing date of the Private Placement.

  • Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
    Zacks

    Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates

    FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.

  • PR Newswire

    CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

    Not intended for US, Canada and UK-based media   Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with ...

  • GuruFocus.com

    US Indexes Close Mostly Flat Thursday

    Nasdaq gains 0.07% Continue reading...

  • GlobeNewswire

    BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

    Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp. (BCT.V) (BCTXF) will remain halted for the duration of CEO Dr. Williams’ presentation. Robust responder experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain – tumors that had metastasized to areas outside of her breasts. Prior to the Combination Study of Bria-IMT™ with KEYTRUDA®, she had failed prior regimens with 16 agents (13 chemotherapy and 3 hormonal).

  • Dow Jones Today: Fed Obliges, Stocks Don’t
    InvestorPlace

    Dow Jones Today: Fed Obliges, Stocks Don’t

    As was widely expected, the Federal Reserve lowered interest rates today by 25 basis points, but that wasn't enough to spark upside for equities. Nor was it enough for President Donald Trump who criticized the Fed for lacking "sense" and "vision" because it didn't lower rates by 50 basis points.Source: rafapress / Shutterstock.com Three Fed governors voted against today's rate cut, prompting some investors to express concern about the path forward."In determining the timing and size of future adjustments to the target range for the federal funds rate, the Committee will assess realized and expected economic conditions relative to its maximum employment objective and its symmetric 2 percent inflation objective," the Federal Open Market Committee wrote in a statement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis assessment will take into account a wide range of information, including measures of labor market conditions, indicators of inflation pressures and expectations, and readings on financial and international developments.So today the Nasdaq Composite slipped 0.1% while the S&P 500 added just 0.03%. The Dow Jones Industrial Average gained 0.1%. In late trading, half of the Dow stocks were pointed higher. The only sector in the U.S. that closed higher today was, unsurprisingly, utilities. Small Winners CircleThere weren't many Dow winners today and among that small group, the gains were, well, small. One surprise was JPMorgan Chase (NYSE:JPM). Financial services stocks usually benefit from higher interest rates, and JPM and its rival banks have recently been complaining about the effects lower rates have on their net interest margins. In late trading JPM was the only financial services name in the Dow trading higher. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Another surprise, though of the disappointing variety, was Merck (NYSE:MRK). This Dow component barely nudged higher despite some encouraging news about its Keytruda cancer treatment. Regulators in Australia, Canada and the U.S. approved Keytruda to treat advanced endometrial carcinoma.This is significant news, but the stock barely moved higher today. Hey, it's not everyday three major developed markets approve a cancer treatment on the same day."Merck said regulators approved the use of Keytruda with a drug called Lenvima, discovered by the Japanese company Eisai (OTCMKTS:ESALY), to treat some instances of advanced endometrial carcinoma, a serious condition for which patients currently have few options," Josh Nathan-Kazis wrote for Barron's.Procter & Gamble (NYSE:PG) was a Dow winner today, and like the others, it was in modest fashion. P&G is one of the Dow's best-performing names this year. And some traders are getting bullish about options on the consumer goods giant's shares. Apple, AgainYes, Apple (NASDAQ:AAPL) has been making a lot of appearances here in recent days -- and the iPhone maker is back today. Wedbush released a note earlier today forecasting 185 million in iPhone 11 shipments for fiscal 2020. Analysts also wrote that pre-orders for the phone in the U.S. have been strong.Up nearly 8% this month, Apple has been one of the best-performing Dow stocks in September. Bottom Line on the Dow Jones TodayIt's clear that market participants are focusing on the Fed's division. However, because the central bank did not cut by 50 basis points today, it has another 25 basis point cut in its back pocket. Chairman Jerome Powell overtly said that the Fed can deploy more rate reductions if the economy sours, which he doesn't see happening right now.Speaking of the economy, the Fed upped its 2019 gross domestic product forecast to growth of 2.2%. That's up slightly from June's estimate of 2.1%. For now, the central bank is standing firm on its forecast of 2% GDP growth in 2020.As of this writing, Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Dow Jones Today: Fed Obliges, Stocks Don't appeared first on InvestorPlace.

  • 10 Companies Making Their CEOs Rich
    InvestorPlace

    10 Companies Making Their CEOs Rich

    The headline "The Stock-Buyback Swindle" says it all. The Atlantic magazine's August issue had a story about how American companies are spending trillions on stock buybacks to enrich their CEOs. Much of the article's content has been covered extensively by business media -- both the pros and cons -- so I won't rehash the arguments. However, one of author Jerry Useem's paragraphs bears repeating because it hits at the core of the problem."Corporations describe the practice as an efficient way to return money to shareholders," Useem wrote. "By reducing the number of shares outstanding in the market, a buyback lifts the price of each remaining share. But that spike is often short-lived: A study by the research firm Fortuna Advisors found that, five years out, the stocks of companies that engaged in heavy buybacks performed worse for shareholders than the stocks of companies that didn't."InvestorPlace - Stock Market News, Stock Advice & Trading TipsI've always believed that if a company wants to allocate its free cash flow to shareholders, it should do so by paying a special dividend, not by repurchasing shares or paying a regular dividend. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Stock buybacks distort earnings growth while regular quarterly dividends ratchet up shareholder expectations. Neither is good for the long-term health of a business. But it's especially galling when stock buybacks enrich a CEO at the expense of the rank-and-file employees.Love them or hate them, these 10 companies are making their CEOs rich. Stock Buybacks Making CEOs Rich: Oracle (ORCL)Source: JHVEPhoto / Shutterstock.com According to the Equilar 200 study, Oracle (NASDAQ:ORCL) co-CEOs Mark Hurd and Safra Catz earned a combined $298 million in total compensation in fiscal 2017 and 2018, of which approximately 96% came from stock grants and option awards. In 2018, Hurd and Catz were paid 1,205 times the company's median pay of $89,887. As a tandem, Hurd and Catz own 49.7 million shares, which are worth $2.7 billion at current prices. The duo's compensation in 2017 and 2018 fails to take into consideration the amount paid through vested shares. Catz received $158 million in shares that vested in fiscal 2018 alone. As for share repurchases, the company repurchased $51 billion of its stock over the past three fiscal years, reducing its share count by 14%. Not surprisingly, its earnings per share increased by 43% over the same period. JPMorgan (JPM)Source: Bjorn Bakstad / Shutterstock.com JPMorgan (NYSE:JPM) CEO James Dimon earned $58 million in total compensation in fiscal 2017 and 2018, approximately 77% of it from stock grants. In 2018, Dimon was paid 381 times the company's median pay of $78,923.Dimon owns 10 million shares if you include options, which are worth $1.2 billion at current prices. In 2018 alone, the JPMorgan CEO had $11 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $44.5 billion of its stock over the past three fiscal years, reducing its share count by 10%. JPMorgan increased its earnings per share by 50% over the same period. Microsoft (MSFT)Source: gguy / Shutterstock.com Microsoft (NASDAQ:MSFT) CEO Satya Nadella earned $46 million in total compensation in fiscal 2017 and 2018, approximately 61% of it from stock grants and option awards. In 2018, Nadella was paid a relatively reasonable 154 times the company's median pay of $167,689.Nadella owns 2.9 million shares if you include options, which are worth $393.6 million at current prices. In 2018 alone, Nadella had $25.8 million in Microsoft stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $42 billion of its stock over the past three fiscal years, reducing its share count by 3%. That's not surprising given how much stock the company issues to employees for a job well done. Microsoft managed to increase its earnings per share by 98% over the same period. Merck (MRK)Source: JHVEPhoto / Shutterstock.com Merck (NYSE:MRK) CEO Kenneth Frazier earned $38 million in total compensation in fiscal 2017 and 2018, approximately 68% of it from stock grants and option awards. In 2018, Frazier was paid 215 times the company's median pay of $82,173.Frazier owns 3.7 million shares if you include options, which are worth $307.5 million at current prices. In 2018 alone, the Merck CEO had $41.3 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $16.5 billion of its stock over the past three fiscal years, reducing its share count by 6%. Merck managed to increase its earnings per share by 49% over the same period. However, its GAAP results have been very choppy over the past decade. You'll want to take this with a grain of salt. Apple (AAPL)Source: View Apart / Shutterstock.com According to the 2018 version of the Equilar 200, a list of the 200 highest-paid CEOs in America, Apple (NASDAQ:AAPL) CEO Tim Cook made $29 million in total compensation in fiscal 2017 and 2018, none of it from stock grants or options. In 2018, Cook was paid 283 times the company's median pay of $55,426. However, one needn't feel sorry for Cook. He owns 878,425 shares of Apple stock worth $198 million as (as of Sept. 12). In addition, Cook has had more than a million shares of AAPL stock vest in the last two years alone. This means his compensation for 2017 and 2018 was actually much higher than $29 million. As for share repurchases, the company repurchased $135.3 billion of its stock over the past three fiscal years, reducing its share count by 14%. Not surprisingly, its earnings per share increased by 29% over the same period. Bank of America (BAC)Source: 4kclips / Shutterstock.com Bank of America (NYSE:BAC) CEO Brian Moynihan earned $43 million in total compensation in fiscal 2017 and 2018, approximately 93% of it from stock grants and option awards. In 2018, Moynihan was paid 247 times the company's median pay of $92,040.Moynihan owns 3.4 million shares if you include options, which are worth $100.9 million at current prices. In 2018 alone, Moynihan had $23.1 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $38 billion of its stock over the past three fiscal years, reducing its share count by 9%. Bank of America increased its earnings per share by 99% over the same period. eBay (EBAY)Source: Mano Kors / Shutterstock.com eBay (NASDAQ:EBAY) CEO Devin Wenig earned $36 million in total compensation in fiscal 2017 and 2018, approximately 82% of it from stock grants and option awards. In 2018, Wenig was paid a 152 times the company's median pay of $119,562.Wenig owns 1.7 million shares if you include options, which are worth $67.5 million at current prices. In 2018, Wenig had $18.8 million in eBay stock vest on top of his total compensation. As for share repurchases, the company repurchased $10.1 billion of its stock over the past three fiscal years, reducing its share count by 19%. eBay increased its earnings per share by 80% over the same period. Qualcomm (QCOM)Source: photobyphm / Shutterstock.com Qualcomm (NASDAQ:QCOM) CEO Steven Mollenkopf earned $32 million in total compensation in fiscal 2017 and 2018, approximately 75% of it from stock grants and option awards. In 2018, Mollenkopf was paid a 233 times the company's median pay of $85,592.Mollenkopf owns 679,813 shares if you include options, which are worth $53.8 million at current prices. In 2018 alone, the CEO had $12.9 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $27.8 billion of its stock over the past three fiscal years, reducing its share count by 11%. Qualcomm decreased its earnings per share by 203% over the same period. On a non-GAAP basis, it decreased earnings per share by 21%. Pfizer (PFE)Source: Manuel Esteban / Shutterstock.com Pfizer (NYSE:PFE) CEO Ian Read earned $46 million in total compensation in fiscal 2017 and 2018, approximately 76% of it from stock grants and option awards. In January 2019, Read passed down the company to Albert Bourla after eight years at Pfizer's helm. In 2018, Read was paid 244 times the company's median pay of $80,011.Read owns 1.3 million shares if you include options, which are worth $48.5 million at current prices. In 2018 alone, Read had $10.6 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $22.2 billion of its stock over the past three fiscal years, reducing its share count by 5%. Pfizer increased its earnings per share by 68% over the same period. Cisco (CSCO)Source: Sundry Photography / Shutterstock.com Cisco (NASDAQ:CSCO) CEO Charles Robbins earned $38 million in total compensation in fiscal 2017 and 2018, approximately 73% of it from stock grants and option awards. In 2018, Robbins was paid 160 times the company's median pay of $132,764, the second-highest median pay (behind Microsoft) of the 10 stocks listed in this article. Robbins owns 139,189 shares if you include options, which are worth $6.9 million at current prices. Of the CEOs on this list, Robbins has the smallest ownership position in terms of total dollars in stock held. In 2018, Robbins had $9 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $41.9 billion of its stock over the past three fiscal years, reducing its share count by 13%. Cisco increased its earnings per share by 24% over the same period. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post 10 Companies Making Their CEOs Rich appeared first on InvestorPlace.

  • Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
    Zacks

    Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma

    Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.

  • Benzinga

    NewLink Genetics Rallies After Ebola Vaccine Granted Priority Review Status

    Potential approval of the vaccine will trigger issuance of a priority review voucher owned by Merck and in which NewLink has a substantial economic interest. The priority review voucher program was created by the U.S. Congress in 2007, and under the program, on approval of a treatment for a neglected or rare pediatric disease, the developer will be issued a voucher for priority review for a different drug as a means of incentivizing development of treatments for neglected and rare diseases. "We are pleased with this morning's announcement from our partner, Merck.

  • Business Wire

    FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High or Mismatch Repair Deficient , Who Have Di

  • Merck (MRK) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Merck (MRK) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Merck (MRK) closed at $82.51, marking a +0.59% move from the previous day.

  • Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
    Zacks

    Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

    The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

  • J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
    Zacks

    J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis

    J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.

  • Business Wire

    FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus

    Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Merck’s investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus. In July 2016, the FDA granted Breakthrough Therapy Designation to V920.